Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 4,600 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Elena Ridloff sold 4,600 shares of Kymera Therapeutics stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $85.42, for a total transaction of $392,932.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Elena Ridloff also recently made the following trade(s):

• On Tuesday, March 31st, Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock. The stock was sold at an average price of $85.37, for a total transaction of $631,738.00.

Kymera Therapeutics Trading Down 0.2%

Kymera Therapeutics stock traded down $0.16 during midday trading on Thursday, reaching $84.77. The stock had a trading volume of 114,596 shares, compared to its average volume of 761,006. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00. The company has a fifty day moving average price of $81.01 and a two-hundred day moving average price of $71.64. The company has a market capitalization of $6.92 billion, a P/E ratio of -23.04 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. During the same period in the previous year, the company earned ($0.88) earnings per share. Kymera Therapeutics’s revenue for the quarter was down 60.8% compared to the same quarter last year. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KYMR has been the subject of several analyst reports. Oppenheimer increased their price objective on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. BTIG Research lowered their price target on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Truist Financial lifted their price objective on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Leerink Partners increased their target price on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Finally, Bank of America boosted their price target on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.90.

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds have recently made changes to their positions in the business. PNC Financial Services Group Inc. boosted its holdings in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after buying an additional 770 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares during the last quarter. Larson Financial Group LLC lifted its holdings in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares during the last quarter. Osaic Holdings Inc. boosted its position in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the period. Finally, Bessemer Group Inc. raised its position in shares of Kymera Therapeutics by 652.0% in the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after purchasing an additional 815 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.